CHANGES IN THE HEMOSTATIC SYSTEM AGAINST THE BACKGROUND OF VARIOUS TREATMENT REGIMENS IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES

Ivan Tverdovsky, Ivan Tutrin, Oleg Tarabrin

Abstract


About 2–3 % of the population and about 35–50 % of people over 65 years suffer from obliterating atherosclerosis of the main arteries of the lower extremities. There are many known factors that potentiate atherosclerosis. Some of them are referred to as leading, such as hyperlipoproteinemia or hypertension, others to concomitant contributing to the defeat of the arteries. According to J.S.A. Fuchs include hypertension, hypercholesterolemia and smoking as major risk factors for atherosclerosis. They are less affected by obesity, diabetes, hypertriglyceridemia, sedentary lifestyle, stress

Objective of the study. The purpose of this study is to evaluate the functional status of the vascular – platelet, coagulation and fibrinolysis of the hemostasis system and their disorders using low – frequency piezoelectric thromboelastography (LPTEG) in patients with obliterating atherosclerosis of the lower extremities on the background of treatment.

Materials and methods. The initial state of the hemostasis system was evaluated in 90 patients undergoing treatment for obliterating atherosclerosis of the lower extremities in the Odessa Regional Clinical Hospital and MD Odreks. All patients underwent surgery in the amount of femoral-popliteal autologous bypass grafting. Patients in the control (1st) group (45 patients) received analgesia during surgery and in the postoperative period based on epidural administration of bupivacaine, and their treatment regimen included enoxaparin 0.4 ml (40,000 anti-XA ME) 2 times a day subcutaneously into the anterolateral surface of the abdominal wall from the first postoperative day and pentoxifylline IV 200 mg twice a day for 7 days. Patients of the studied (2nd) group (45 patients) received analgesia during surgery and in the postoperative period on the basis of epidural administration of bupivacaine, also rivaroxaban 15 mg 2 times a day oraly on the first postoperative day was included in their treatment regimen.

The dynamics of the state of the hemostatic system in both groups of patients with OA was evaluated using LPTEG in the first day before surgery and on the 3rd, 5th and 7th postoperative days.

Results and conclusions. Before surgery and the start of treatment in patients with OA, against the background of activation of the vascular - platelet link of hemostasis, significant structural and chronometric hypercoagulation with increased thrombin generation and activation of blood fibrinolytic activity are noted. Against the background of treatment in the 1st group, platelet aggregation tends to normalize and there are significant differences compared with the indicators before treatment in the 1st group, the vascular-platelet and fibrinolytic systems did not reach normal values before 7 days, but showed a significant downward trend the degree of manifestation of their violations. Against the background of treatment of the 2nd group, significant changes were observed towards normalization in all components of the hemostatic system according to the LPTEG technique. The state of the coagulation unit of the hemostasis system in patients with OA on the 7th day of therapy does not significantly differ from the norm, it is possible to note significant shifts towards hypocoagulation within the normal range. The fibrinolytic system on the 7th day of treatment does not statistically differ from normal indicators, it has significant positive dynamics compared to 1 day. The second group revealed a statistically significant normalization of all indicators characterizing the blood coagulation potential of the blood and the aggregation ability of platelets, as well as the indicator that is responsible for changes in the fibrinolytic blood system.


Keywords


obliterating atherosclerosis; thrombus formation; hemostasis

Full Text:

PDF

References


Hess, C. N., Norgren, L., Ansel, G. M., Capell, W. H., Fletcher, J. P., Fowkes, F. G. R. et. al. (2017). A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation, 135 (25), 2534–2555. doi: http://doi.org/10.1161/circulationaha.117.024469

Zannad, F., Bauersachs, R. (2018). Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection? Thrombosis and Haemostasis, 118 (S 01), S12–S22. doi: http://doi.org/10.1055/s-0038-1636530

Anand, S. (2017). On Behalf of COMPASS Investigators. Rivaroxaban in stable peripheral or carotid artery disease. Presented at the European Society of Cardiology Congress 2017. Barcelona.

Harwood, A.-E., Smith, G. E., Cayton, T., Broadbent, E., Chetter, I. C. (2016). A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. Annals of Vascular Surgery, 34, 280–289. doi: http://doi.org/10.1016/j.avsg.2016.02.009

Layden, J., Michaels, J., Bermingham, S., Higgins, B. (2012). Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ, 345 (1), e4947. doi: http://doi.org/10.1136/bmj.e4947

Creager, M. A., Libby, P. (2012). Peripheral Artery Diseases. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: Elsevier 1338–1358. doi: http://doi.org/10.1016/b978-1-4377-0398-6.00061-5

Secemsky, E. A., Schermerhorn, M., Carroll, B. J., Kennedy, K. F., Shen, C., Valsdottir, L. R. et. al. (2017). Readmissions After Revascularization Procedures for Peripheral Arterial Disease. Annals of Internal Medicine, 168 (2), 93–99. doi: http://doi.org/10.7326/m17-1058

Gavrilenko, A. V., Al-Yousef, N. N., Wang, X., Mamedova, N. M., Ananieva, M. V., Li, R. (2019). Profundoplasty in treatment of patients with chronic lower limb ischaemia. Angiology and Vascular Surgery, 25 (3), 122–127. doi: http://doi.org/10.33529/angio2019308

Fowkes, F. G. R., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M. et. al. (2013). Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet, 382 (9901), 1329–1340. doi: http://doi.org/10.1016/s0140-6736(13)61249-0

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O. et. al. (2017). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 377 (14), 1319–1330. doi: http://doi.org/10.1056/nejmoa1709118

Giatti, L., Camelo, L. do V., Rodrigues, J. F. de C., Barreto, S. M. (2012). Reliability of the MacArthur scale of subjective social status – Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). BMC Public Health, 12 (1). doi: http://doi.org/10.1186/1471-2458-12-1096

Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L. K. et. al. (2011). 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). Journal of the American College of Cardiology, 58 (19), 2020–2045. doi: http://doi.org/10.1016/j.jacc.2011.08.023

Prévost, A., Lafitte, M., Pucheu, Y., Couffinhal, T. (2013). Education and home based training for intermittent claudication: functional effects and quality of life. European Journal of Preventive Cardiology, 22 (3), 373–379. doi: http://doi.org/10.1177/2047487313512217

McDermott, M. M. (2013). Functional Impairment in Peripheral Artery Disease and How to Improve It in 2013. Current Cardiology Reports, 15 (4). doi: http://doi.org/10.1007/s11886-013-0347-5

Kullo, I. J., Rooke, T. W. (2016). Peripheral Artery Disease. New England Journal of Medicine, 374 (9), 861–871. doi: http://doi.org/10.1056/nejmcp1507631

Kearon, C., Akl, E. A., Comerota, A. J., Prandoni, P., Bounameaux, H., Goldhaber, S. Z. et. al. (2012). Antithrombotic Therapy for VTE Disease. Chest, 141 (2), e419S–e496S. doi: http://doi.org/10.1378/chest.11-2301

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F. et. al. (2018). Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet, 391 (10117), 205–218. doi: http://doi.org/10.1016/s0140-6736(17)32458-3

Tarabrin, O., Shcherbakov, S., Gavrychenko, D., Saleh, O., Lyoshenko, I., Kushnir, O. (2013). How to control the coagulation disorders? European Journal of Anaesthesiology, 30, 92–92. doi: http://doi.org/10.1097/00003643-201306001-00285

Tagalakis, V., Patenaude, V., Kahn, S. R., Suissa, S. (2013). Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort. The American Journal of Medicine, 126 (9), 13–21. doi: http://doi.org/10.1016/j.amjmed.2013.02.024

Sapelkin, S. V., Kuznetsov, M. R. (2016). Konservativnoye lecheniye bol'nykh s zabolevaniyami perifericheskikh arteriy: vozmozhnosti i sushchestvuyushchiye problemy. Angiologiya i sosudistaya khirurgiya, 4, 169–175.

Ferreira, V., Freixo, C., Gonçalves, J., Teixeira, G., Antunes, I., Veiga, C. et. al. (2019). Effectiveness and Safety of Rivaroxaban Compared to Acenocumarol after Infrainguinal Surgical Revascularization. Annals of Vascular Surgery, 55, 78–84. doi: http://doi.org/10.1016/j.avsg.2018.06.008

Halle, T. R., Benarroch-Gampel, J., Teodorescu, V. J., Rajani, R. R. (2018). Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient Compliance with Recommended Medical Therapy. Annals of Vascular Surgery, 46, 104–111. doi: http://doi.org/10.1016/j.avsg.2017.06.152

Bhagirath, V. C., Eikelboom, J. W., Anand, S. S. (2018). Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology, 14 (6), 443–453. doi: http://doi.org/10.2217/fca-2018-0059




DOI: http://dx.doi.org/10.21303/2504-5679.2019.001084

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Ivan Tverdovsky, Ivan Tutrin, Oleg Tarabrin

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)